Press Releases

Press Releases
Feb 05, 2021
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day
Feb 01, 2021
CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer
Dec 14, 2020
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
Nov 24, 2020
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 16, 2020
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
Oct 28, 2020
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
Oct 07, 2020
Jul 27, 2020
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
May 15, 2020
May 07, 2020
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
Apr 28, 2020
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
Feb 12, 2020
Oct 28, 2019
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
Jul 29, 2019
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
Apr 29, 2019
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
Apr 16, 2019
Feb 27, 2019
Feb 25, 2019
Nov 09, 2018
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
Nov 07, 2018
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
Aug 07, 2018
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results
Aug 07, 2018
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results
May 08, 2018
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
Apr 16, 2018
Apr 13, 2018
CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018
Apr 04, 2018
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
Mar 08, 2018
Nov 13, 2017
CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer
Nov 13, 2017
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs
Nov 08, 2017
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update
Oct 02, 2017
CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer
Aug 10, 2017
CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update
May 11, 2017
May 08, 2017
CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
Apr 26, 2017
Apr 17, 2017
Mar 14, 2017
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte
Mar 10, 2017
Mar 10, 2016
Sep 30, 2015
FierceBiotech names CRISPR Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
Nov 10, 2014

You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.